MindWalk Holdings (HYFT) Net Margin (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Net Margin of 0.0% for Q2 2026, down 2.0% year-over-year from 0.0% in Q2 2025, and up 28.55% quarter-over-quarter from 0.0% in Q4 2025.
MindWalk Holdings (HYFT) Net Margin (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Net Margin for 7 consecutive years, with 0.0% the latest figure, recorded in Q2 2026.
- In Q2 2026, Net Margin fell 2.0% year-over-year to 0.0%; the TTM figure through Apr 2026 stood at 13.74% (up 1140.0% YoY), while the FY2026 annual figure was 7.41%, down 2000.0% from the prior year.
- Net Margin improved to 0.0% in Q2 2026 per HYFT's latest filing, from 0.0% in the prior quarter.
- Across five years, Net Margin topped out at 73329.82% in Q3 2023 and bottomed at 792.14% in Q2 2023.
- Historically, Net Margin has averaged 8075.72% across 5 years, with a median of 15.8% in 2025.
- Annual changes were most pronounced in 2022 — Net Margin jumped 2000000000 bps — and 2024, when it plunged 7332120 bps.
- MindWalk Holdings' Net Margin stood at 100.81% in 2022, then soared by 28369 bps to 28699.19% in 2023, then plunged by 100 bps to 37.1% in 2024, then slumped by 100 bps to 0.0% in 2025, then increased by 29 bps to 0.0% in 2026.
- Business Quant data shows HYFT's Net Margin at 0.0% in Q2 2026, 0.0% in Q4 2025, and 35716.55% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -20,152.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 0.00% |
| Oct 31, 2025 | 0.00% |
| Jul 31, 2025 | 35,716.55% |
| Apr 30, 2025 | 0.02% |
| Jan 31, 2025 | 15.80% |
| Oct 31, 2024 | 37.10% |
| Jul 31, 2024 | 8.61% |
| Apr 30, 2024 | 482.54% |
| Jan 31, 2024 | 37.02% |
| Oct 31, 2023 | 28,699.19% |
| Jul 31, 2023 | 73,329.82% |
| Apr 30, 2023 | -792.14% |
| Jan 31, 2023 | 20.40% |
| Oct 31, 2022 | 100.81% |
| Jul 31, 2022 | 8.35% |
| Apr 30, 2022 | -372.38% |
| Jan 31, 2022 | -4.40% |
| Oct 31, 2021 | -114.38% |
| Jul 31, 2021 | -68.79% |
| Apr 30, 2021 | -92,766,858.08% |